(Q37870670)

24 August 2017

1 reference

title

Priorities in Parkinson's disease research (English)

1 reference

24 August 2017

1 reference

3

Thomas Gasser

1 reference

24 August 2017

Wassilios G. Meissner

Wassilios G Meissner

1

0 references

Valerie Voon

Valerie Voon

10

0 references

Erwan Bezard

Erwan Bezard

13

0 references

Olivier Rascol

8

Olivier Rascol

1 reference

24 August 2017

5

Andres Lozano

1 reference

24 August 2017

4

Christopher G Goetz

1 reference

24 August 2017

9

Anthony Schapira

1 reference

24 August 2017

6

Paola Piccini

1 reference

24 August 2017

Mark Frasier

2

1 reference

24 August 2017

José A Obeso

7

1 reference

24 August 2017

David M Weiner

11

1 reference

24 August 2017

François Tison

12

1 reference

24 August 2017

1 May 2011

1 reference

Nature Reviews Drug Discovery

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

5

1 reference

24 August 2017

377-393

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3430

24 August 2017

0 references

cites work

A randomized trial of deep-brain stimulation for Parkinson's disease.

1 reference

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

31 March 2020

1 reference

Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.

31 March 2020

1 reference

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

31 March 2020

1 reference

Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

31 March 2020

1 reference

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

31 March 2020

1 reference

An essay on the shaking palsy. 1817.

31 March 2020

1 reference

Parkinson's disease: clinical features and diagnosis

31 March 2020

1 reference

Levodopa-induced dyskinesias

31 March 2020

1 reference

Classification of fluctuations in patients with Parkinson's disease

31 March 2020

1 reference

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

31 March 2020

1 reference

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

31 March 2020

1 reference

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

31 March 2020

1 reference

Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations

31 March 2020

1 reference

Effects of expectation on placebo-induced dopamine release in Parkinson disease

31 March 2020

1 reference

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

31 March 2020

1 reference

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

31 March 2020

1 reference

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

31 March 2020

1 reference

Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease.

31 March 2020

1 reference

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease.

31 March 2020

1 reference

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

31 March 2020

1 reference

Pathological gambling in Parkinson disease is reduced by amantadine

31 March 2020

1 reference

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

31 March 2020

1 reference

Clinical diagnostic criteria for dementia associated with Parkinson's disease

31 March 2020

1 reference

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

31 March 2020

1 reference

Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

31 March 2020

1 reference

Rivastigmine for dementia associated with Parkinson's disease

31 March 2020

1 reference

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

31 March 2020

1 reference

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

Memantine in moderate-to-severe Alzheimer's disease

31 March 2020

1 reference

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

31 March 2020

1 reference

Non-motor symptoms of Parkinson's disease: diagnosis and management

31 March 2020

1 reference

Neuropsychiatric symptoms in Parkinson's disease

31 March 2020

1 reference

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

31 March 2020

1 reference

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

A controlled trial of antidepressants in patients with Parkinson disease and depression

31 March 2020

1 reference

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

31 March 2020

1 reference

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

31 March 2020

1 reference

Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

31 March 2020

1 reference

Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

Current therapeutic targets for the treatment of Alzheimer's disease

31 March 2020

1 reference

Molecular and clinical prodrome of Parkinson disease: implications for treatment

31 March 2020

1 reference

Mitochondrial complex I deficiency in Parkinson's disease

31 March 2020

1 reference

Mitochondrial complex I deficiency in Parkinson's disease

31 March 2020

1 reference

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

31 March 2020

1 reference

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

31 March 2020

1 reference

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

31 March 2020

1 reference

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

31 March 2020

1 reference

alpha-Synuclein locus triplication causes Parkinson's disease

31 March 2020

1 reference

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

31 March 2020

1 reference

The Parkinson disease gene LRRK2: evolutionary and structural insights

31 March 2020

1 reference

Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

31 March 2020

1 reference

Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36

31 March 2020

1 reference

Genome-wide association study reveals genetic risk underlying Parkinson's disease

31 March 2020

1 reference

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

31 March 2020

1 reference

Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease

31 March 2020

1 reference

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study

31 March 2020

1 reference

LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study

31 March 2020

1 reference

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

31 March 2020

1 reference

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

31 March 2020

1 reference

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

31 March 2020

1 reference

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1

31 March 2020

1 reference

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

31 March 2020

1 reference

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

31 March 2020

1 reference

Novel pharmacological targets for the treatment of Parkinson's disease

31 March 2020

1 reference

Non-dopaminergic treatments in development for Parkinson's disease

31 March 2020

1 reference

Safinamide in the treatment of Parkinson's disease

31 March 2020

1 reference

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

31 March 2020

1 reference

Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

31 March 2020

1 reference

Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.

31 March 2020

1 reference

Caffeine and progression of Parkinson disease

31 March 2020

1 reference

31 March 2020

1 reference

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

31 March 2020

1 reference

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

31 March 2020

1 reference

Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.

31 March 2020

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

31 March 2020

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

31 March 2020

1 reference

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

31 March 2020

1 reference

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

31 March 2020

1 reference

Placebo influences on dyskinesia in Parkinson's disease

31 March 2020

1 reference

Proceedings and abstracts of the 3rd Congress of the Asian Society for Stereotactic, Functional and Computer-Assisted Neurosurgery. Seoul, Korea, June 13-16, 1999

31 March 2020

1 reference

Desynchronizing the abnormally synchronized neural activity in the subthalamic nucleus: a modeling study

31 March 2020

1 reference

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

31 March 2020

1 reference

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

31 March 2020

1 reference

Effect of deprenyl on the progression of disability in early Parkinson's disease

31 March 2020

1 reference

Levodopa and the progression of Parkinson's disease

31 March 2020

1 reference

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

31 March 2020

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

31 March 2020

1 reference

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

31 March 2020

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

31 March 2020

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

31 March 2020

1 reference

The role of radiotracer imaging in Parkinson disease

31 March 2020

1 reference

How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?

31 March 2020

1 reference

The metabolic topography of parkinsonism

31 March 2020

1 reference

FDG PET in the differential diagnosis of parkinsonian disorders

31 March 2020

1 reference

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

31 March 2020

1 reference

In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy

31 March 2020

1 reference

Midbrain iron content in early Parkinson disease: a potential biomarker of disease status

31 March 2020

1 reference

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

31 March 2020

1 reference

Transcranial sonography in movement disorders

31 March 2020

1 reference

Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

31 March 2020

1 reference

Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach

31 March 2020

1 reference

Molecular markers of early Parkinson's disease based on gene expression in blood

31 March 2020

1 reference

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

31 March 2020

1 reference

Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

31 March 2020

1 reference

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

31 March 2020

1 reference

When does Parkinson disease start?

31 March 2020

1 reference

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

31 March 2020

1 reference

Multiple system atrophy: an update.

31 March 2020

1 reference

SNCA variants are associated with increased risk for multiple system atrophy

31 March 2020

1 reference

Second consensus statement on the diagnosis of multiple system atrophy

31 March 2020

1 reference

Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).

31 March 2020

1 reference

Measuring health-related quality of life in MSA: the MSA-QoL.

31 March 2020

1 reference

Animal models of multiple system atrophy.

31 March 2020

1 reference

Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study

31 March 2020

1 reference

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).

31 March 2020

1 reference

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

31 March 2020

1 reference

The Unified Dyskinesia Rating Scale: presentation and clinimetric profile

31 March 2020

1 reference

Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure

31 March 2020

1 reference

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

31 March 2020

1 reference

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

31 March 2020

1 reference

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

31 March 2020

1 reference

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

31 March 2020

1 reference

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

31 March 2020

1 reference

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

31 March 2020

1 reference

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

31 March 2020

1 reference

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

31 March 2020

1 reference

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

31 March 2020

1 reference

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

31 March 2020

1 reference

Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study

31 March 2020

1 reference

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

31 March 2020

1 reference

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

31 March 2020

1 reference

Interpreting the results of Parkinson's disease clinical trials: time for a change

31 March 2020

1 reference

12 December 2020

Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27

1 reference

12 December 2020

Etiopathogenesis and treatment of Parkinson's disease

1 reference

12 December 2020

Forty-five years of stereotactic surgery for Parkinson's disease: a review.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3430

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference